A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
Latest Information Update: 19 Feb 2025
At a glance
- Drugs VK 2735 (Primary)
- Indications Obesity; Weight loss
- Focus Therapeutic Use
- Acronyms VENTURE
- Sponsors Viking Therapeutics
- 12 Feb 2025 Status changed from active, no longer recruiting to completed.
- 04 Nov 2024 According to a Viking Therapeutics media release, data from this trial will be presented at Obesity Week 2024
- 04 Nov 2024 Results published in the Viking Therapeutics Media Release